Biological therapies for atopic dermatitis: An update�(Review)
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Severe atopic dermatitis, which affects both adults and children, is a debilitating disorder with a significant decline of patients' quality of life. Although aetiopathogenic factors are currently a topic of study and interpretation, the main features of atopic eczema are skin barrier disturbance and immune dysregulation. Severe refractory disease that fails to improve with conventional therapy may benefit from biologic therapy. Progress in understanding immunopathology of atopic dermatitis have allowed identification of therapeutic molecular targets in the field of biological therapy. We reviewed the different biological treatments with a focus on novel targeted agents: Systemic immunotherapy (Omalizumab, Dupilumab, Lebrikizumab, Tralokinumab, Nemolizumab, Ustekinumab, Fezakinumab, Tezepelumab, Apremilast, allergen specific immunotherapy), and topical agents (Tofacitinib, Crisaborole).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“control groups investigated the efficacy and safety of Dupilumab in AD (50-57).”
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Kim, B. E., Leung, D. Y. M., Boguniewicz, M., & Howell, M. D. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.006 · Cited by 538
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339 · cited 1×
“…monoclonal anti-IL-5 antibody, Rituximab, a chimeric monoclonal antibody against CD20, a pan marker of B lymphocytes, as well as inhibitors of tumour necrosis-α factor/receptor (TNF-α ), such as Infliximab, Etanercept, and Adalimumab, brought moderate and intermittent improvement of AD (82-87).”
Mortz, C. G., Andersen, K. E., Dellgren, C., Barington, T., & Bindslev‐Jensen, C. (2015) · Allergy · doi:10.1111/all.12619 · Cited by 267
Th2 Cytokines Act on S100/A11 to Downregulate Keratinocyte Differentiation
Howell, M. D., Fairchild, H. R., Kim, B. E., Bin, L., Boguniewicz, M., Redzic, J. S., Hansen, K. C., & Leung, D. Y. M. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.74 · Cited by 224 · cited 1×
“Additionally, IL-4 and -13 regulate expression of genes encoding proteins involved in skin susceptibility to skin pathogens (46-48).”
Bae, J. M., Choi, Y. Y., Park, C. O., Chung, K. Y., & Lee, K. H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.044 · Cited by 201
Heil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197 · cited 1×
“Although most data from small randomized trials, case series and case reports documented clinical benefit and resolution of eczema, a small number of studies showed no improvement of disease with Omalizumab (24-33).”
Treatment of recalcitrant atopic dermatitis with omalizumab
Lane, J. E., Cheyney, J. M., Lane, T. N., Kent, D. E., & Cohen, D. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.09.030 · Cited by 188 · cited 1×
“Although most data from small randomized trials, case series and case reports documented clinical benefit and resolution of eczema, a small number of studies showed no improvement of disease with Omalizumab (24-33).”
Failure of omalizumab for treatment of severe adult atopic dermatitis
Krathen, R. A., & Hsu, S. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.02.014 · Cited by 172
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
Samrao, A., Berry, T. M., Goreshi, R., & Simpson, E. L. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.812 · Cited by 166 · cited 1×
“Recent clinical trials illustrated the potential for Apremilast as a treat-ment option for AD (79-81).”
Hotze, M., Baurecht, H., Rodríguez, E., Chapman‐Rothe, N., Ollert, M., Fölster‐Holst, R., Adamski, J., Illig, T., Ring, J., & Weidinger, S. (2014) · Allergy · doi:10.1111/all.12234 · Cited by 107
Cited by
Guttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
A basophil-neuronal axis promotes itch
Wang, F., Trier, A. M., Li, F., Kim, S., Chen, Z., Chai, J. N., Mack, M. R., Morrison, S. A., Hamilton, J. D., Baek, J., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.033 · Cited by 264
Martínez, B. A., Shrotri, S., Kingsmore, K. M., Bachali, P., Grammer, A. C., & Lipsky, P. E. (2022) · Science Advances · doi:10.1126/sciadv.abn4776 · Cited by 56
“In contrast, other inflammatory skin diseases, such as psoriasis (PSO), have numerous approved therapies ( 8 ), and dupilumab, an inhibitor of interleukin-4 (IL-4) receptor signaling, is an effective therapy for both atopic dermatitis (AD) and PSO ( 9 ).”
The pathology of type 2 inflammation-associated itch in atopic dermatitis
Moniaga, C. S., Tominaga, M., & Takamori, K. (2021) · Diagnostics · doi:10.3390/diagnostics11112090 · Cited by 28
Metadata
- Authors
- Deleanu, D., & Nedelea, I.
- Venue
- Experimental and Therapeutic Medicine
- Publisher
- Spandidos Publications
- Published
- 2018-11-19
- Volume
- 17
- Issue
- 2
- Pages
- 1061-1067
- ISSN
- 1792-0981 (ISSN-L)
- 1792-1015
- OpenAlex
- W2901626260
- Cited by
- 62
- References
- 13
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.